Close

Stempeutics gets DCGI nod for Phase 3 clinical trial on its product for treating COVID patients

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

Stempeutics, a group company of Manipal Education and Medical Group (MEMG) said it has received DCGI clearance to conduct Phase 3 clinical trial on its product for treating COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

The company will be using its stem cell product, Stempeucel, for conducting the label extension Phase 3 clinical trial.

The product is already approved for marketing for the treatment of critical limb ischemia by the Drugs Controller General of India (DCGI).

Stempeucel exhibits potent immuno-modulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to the cytokine storm elicited by the body’s immune cells in response to SARS-CoV-2 (COVID-19) related infection in the lungs, Stempeutics said in a statement.

“Coronavirus third wave appears to be mild-to-moderate. But the most severely affected CoV-2 infected patients will often go on to develop ARDS which necessitates assisted ventilation to preserve breathing and lung function.

“Moreover, many ARDS patients may also experience an acute inflammatory response (cytokine storm) which can result in long-term damage to lung tissue and lung function,” Stempeutics Chairman Sudarshan Ballal noted.

“Moreover, many ARDS patients may also experience an acute inflammatory response (cytokine storm) which can result in long-term damage to lung tissue and lung function,” Stempeutics Chairman Sudarshan Ballal noted.

Treating ARDS patients with allogeneic expanded bone marrow derived MSCs could alleviate lung inflammation and compromised lung function and significantly reduce the time required for patients to be ventilated, he stated.
“The results of this trial would be very crucial in confirming this,” Ballal said. Headquartered in Bengaluru, Stempeutics is an advanced clinical-stage biotech company.

Latest stories

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back